BCL2 and diffuse large B-cell lymphoma: We checked if our metric could estimate prognostic MYC, BCL2, and BCL6 subpopulations from clinical-grade pathologist scores for chromogenic IHC in a well-characterized cohort of DLBCL from the British Columbia Cancer Agency (BCA; ref. 15).